Trending in Obesity: Lilly Retatrutide, VCT220 and more

This obesity update highlights major clinical and pipeline developments shaping the metabolic disease landscape. Vincentage Pharma reported Phase 3 success for oral GLP-1 candidate VCT220 in China, while Eli Lilly announced pivotal TRIUMPH-1 results for retatrutide. Additional updates include EktaH’s post-GLP-1 rebound program, Newon’s GLP-1 secretion study, Korean MASH candidates advancing toward EASL presentations, Verdiva Bio’s oral amylin programs at ADA, and WHO’s new pathway to expand semaglutide and insulin access in low- and middle-income countries.

Видео Trending in Obesity: Lilly Retatrutide, VCT220 and more канала LucidQuest